150360-26-2

Usage

Uses

Used in Pharmaceutical Industry:
(2R)-2-(4-fluorophenyl)propanoic acid is used as a pharmaceutical compound for its potential anti-inflammatory and analgesic properties, offering therapeutic benefits in managing pain and inflammation.
Used in Organic Synthesis:
(2R)-2-(4-fluorophenyl)propanoic acid is used as a building block in the synthesis of various organic compounds, contributing to the development of new chemical entities with diverse applications.
Used in Fluorine Chemistry:
(2R)-2-(4-fluorophenyl)propanoic acid is used as a starting material for the synthesis of fluorinated compounds, capitalizing on the unique properties of fluorine to enhance the performance of resulting compounds in various chemical and pharmaceutical applications.

Upstream product

• 145983-06-8 α-(p-fluorophenyl)-α-methylmalonic acid 
• 762297-79-0 (4R)-3-[(2R)-2-(4-fluorophenyl)propanoyl]-4-isopropyl-1,3-oxazolidin-2-one 
• 459-22-3 4-fluorophenylacetonitrile 
• 405-99-2 para-fluorostyrene 
• 549532-50-5 2-(4-fluorophenyl)propanal 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 350-40-3 2-(4-fluorophenyl)-1-propene 
• 947383-48-4 (E)-1-fluoro-4-(1-nitroprop-1-en-2-yl)benzene 
• 189445-63-4 2-(4-fluorophenyl)propionaldehyde 
• 766-98-3 1-ethynyl-4-fluorobenzene 
• 64-18-6 formic acid 
• 75908-73-5 (+/-)-2-(4-flurophenyl)propanoic acid 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 50415-71-9 methyl 2-(4-fluorophenyl)propanoate 

Downstream Products

• 1219011-17-2 methyl {(8R)-8-[[(2R)-2-(4-fluorophenyl)propanoyl](methyl)amino]-6,7,8,9-tetrahydropyrido[3,2-b]indolizin-5-yl}acetate 
• 1443763-60-7 (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5,α]pyridin-6-yl)phenyl]propanamide 
• 1443763-62-9 (2R)-2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-α]pyridin-6-yl)phenyl]propanamide 
• 1443763-63-0 4-{[6-(4-{[(2R)-2-(4-fluorophenyl)propanoyl]-amino}phenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-3-methoxy-N-(2,2,2-trifluoroethyl)benzamide 
• 1443763-64-1 4-{[6-(4-{[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-3-methoxybenzamide 
• 1443763-65-2 4-{[6-(4-{[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-3-(2,2,2-trifluoroethoxy)benzamide 
• 1443763-66-3 (2R)-N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)-[1,2,4]triazolo[1,5-α]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)propanamide 
• 1443763-67-4 (2R)-N-[4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}[1,2,4]-triazolo[1,5-α]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)propanamide 
• 1443763-68-5 (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)-phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide 
• 1443763-71-0 (2R)-2-amino-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)-phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]ethanamide 
• 374898-01-8 (R)-1-(4-fluorophenyl)ethylamine 
• 1443763-72-1 4-{[6-(4-{[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-3-methoxy-N,N-dimethylbenzamide 
• 1443763-74-3 (2R)-N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-(2,2,2-trifluoroethoxy)phenyl}amino)[1,2,4]triazolo[1,5-α]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)propanamide 

Relevant academic research and scientific papers

Enantioselective Synthesis of Chiral Carboxylic Acids from Alkynes and Formic Acid by Nickel-Catalyzed Cascade Reactions: Facile Synthesis of Profens

We report a stereoselective conversion of terminal alkynes to α-chiral carboxylic acids using a nickel-catalyzed domino hydrocarboxylation-transfer hydrogenation reaction. A simple nickel/BenzP* catalyst displayed high activity in both steps of regioselective hydrocarboxylation of alkynes and subsequent asymmetric transfer hydrogenation. The reaction was successfully applied in enantioselective preparation of three nonsteroidal anti-inflammatory profens (>90 % ees) and the chiral fragment of AZD2716.

KetoABNO/NOx Cocatalytic Aerobic Oxidation of Aldehydes to Carboxylic Acids and Access to α-Chiral Carboxylic Acids via Sequential Asymmetric Hydroformylation/Oxidation

A method for aerobic oxidation of aldehydes to carboxylic acids has been developed using organic nitroxyl and NOx cocatalysts. KetoABNO (9-azabicyclo[3.3.1]nonan-3-one N-oxyl) and NaNO2 were identified as the optimal nitroxyl and NOx sources, respectively. The mildness of the reaction conditions enables sequential asymmetric hydroformylation of alkenes/aerobic aldehyde oxidation to access α-chiral carboxylic acids without racemization. The scope, utility, and limitations of the oxidation method are further evaluated with a series of achiral aldehydes bearing diverse functional groups.

Substrate Scope Evaluation of the Enantioselective Reduction of β-Alkyl-β-arylnitroalkenes by Old Yellow Enzymes 1-3 for Organic Synthesis Applications

The substrate scope of the old yellow enzyme catalyzed reduction of β-alkyl-β-arylnitroalkenes is investigated. Compounds bearing either alkyl chains of increasing length at the carbon atom in position β to the nitro group or different substituents on the aromatic ring are prepared and submitted to bioreduction, to define the synthetic potential of this enantioselective reaction in the preparation of chiral fine chemicals. The versatility of the resulting nitroalkanes as chiral building blocks is shown by reducing the nitro group into a primary amine and by converting it into a carboxylic acid moiety by Meyer reaction. An "explosion" of chiral products can be observed by combining the highly enantioselective ene-reductase-mediated reduction of nitroalkenes with the chemical versatility of the nitro group.

COMPOUNDS FOR THE TREATMENT OF CANCER

The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, and their use for the treatment and/or prophylaxis of diseases.

Easily accessible TADDOL-derived bisphosphonite ligands: Synthesis and application in the asymmetric hydroformylation of vinylarenes

The synthesis of chiral bidentate bisphosphonite ligands based on the TADDOL motif from readily available starting materials has been developed. Taking advantage of the modular nature of the building blocks, a diverse ligand library has been prepared. Their catalytic potential has been evaluated in the asymmetric hydroformylation of styrene and derivatives. These catalysts showed high activity and provided the aldehydes in high enantiomeric purity.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

Enantioselective synthesis of (R)-2-arylpropanenitriles catalysed by ene-reductases in aqueous media and in biphasic ionic liquid-water systems

The enantioselective reduction of α-methylene nitrile derivatives catalysed by ene-reductases affords the corresponding (R)-2-arylpropanenitriles with high conversion values. The reaction is investigated either in aqueous medium (with an organic cosolvent or by loading the substrate onto hydrophobic resins) or in a biphasic ionic liquid-water system. The use of ionic liquids, herein with isolated ene-reductases, is found to improve the work-up and the substrate recovery method. The synthetic manipulation of the final chiral nitrile derivatives indicates how this biocatalysed method can be exploited for the preparation of a wide range of chiral compounds.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods o f preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS

The present invention relates to substituted triazolopyridine compounds of general formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER

The present invention relates to novel compounds showing an inhibitory effect on Mps-1 kinase, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.